Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
about
Mitochondrial pyruvate transport: a historical perspective and future research directionsIdentification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteinsPruning of the adipocyte peroxisome proliferator-activated receptor γ cistrome by hematopoietic master regulator PU.1Nutrient-deprivation autophagy factor-1 (NAF-1): biochemical properties of a novel cellular target for anti-diabetic drugsAbrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) is associated with increased risk of coronary artery disease: a meta-analysisNovel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets.CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.Photoaffinity labeling in target- and binding-site identificationAn insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.ASXL2 Regulates Glucose, Lipid, and Skeletal Homeostasis.Effect of Global ATGL Knockout on Murine Fasting Glucose KineticsNovel Agents for the Treatment of Type 2 Diabetes.Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site.Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptorsMaternal exercise improves insulin sensitivity in mature rat offspring.Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.PPAR-γ regulates pharmacological but not physiological or pathological osteoclast formation.AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseasesRegulation of pyruvate metabolism in metabolic-related diseases.Mitochondrial target of thiazolidinediones.The TZD insulin sensitizer clue provides a new route into diabetes drug discovery.Review article: new treatments in non-alcoholic fatty liver disease.The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling.Identification of Eupatilin from Artemisia argyi as a Selective PPARα Agonist Using Affinity Selection Ultrafiltration LC-MS.PPARs and nonalcoholic fatty liver disease.Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury.Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice.The liver X receptor agonist T0901317 protects mice from high fat diet-induced obesity and insulin resistance.Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.PPARγ and its Role in Adipocyte Homeostasis and Thiazolidinedione-Mediated Insulin Sensitization.Treating fatty liver disease by modulating mitochondrial pyruvate metabolism.An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors.
P2860
Q28085025-5E96EB91-4ADD-490E-8D34-115DCA8B2A22Q28488095-C86EF0A9-4617-4F14-BBE1-CBC204C63416Q28506146-B0651546-2410-4C29-A1AE-9E4A8A785EB8Q28533246-BB129684-6553-4F23-A6AC-15101B19A316Q33789323-C9455611-FDC3-4FC3-9C1E-D7B0CEC1B001Q34315432-C71D0FEB-DFBD-43F2-8136-42C4225168FFQ34540703-7E994454-D5F8-4196-A482-7EE2AA3B5A60Q34541672-982C051F-3D67-4F52-BB33-2267FD781BF6Q34708337-647782F9-C608-4100-B592-144760864A22Q35086490-1F7E325E-126B-4FBD-BD37-EE994250D8F5Q35549631-7B1851C0-93E5-4FC0-A055-43A744D60CECQ35755747-9297704E-1A6A-4AE7-A958-15ED6CF51A6AQ35756379-4E15C5BA-0B6B-4FA8-A15E-D8D857D3E500Q35864410-836C4CC9-A25F-4541-B24D-3EDFCA7CC711Q35910421-FE697F58-FBCE-477A-A961-A166E16048F4Q36508756-9CA6A730-04B0-401A-893D-129F11D20257Q36705829-57825DD4-0972-40DB-A1E7-9CA9F4100ABDQ36733873-C9C4BACD-3233-48A8-BACF-A172581B1764Q36741705-D3298F2C-C556-412E-96F7-A02554B93CE0Q36747796-DA77C71E-FEAA-4627-9DE0-8E7FD11DB4ECQ37304485-84265613-56EC-44FD-AF7D-DBC2F5748A14Q37528057-2E5DB928-11F0-402D-AB63-F891B6E4B13EQ38026549-96D6C8A8-4A87-446A-9483-284B5D5D7C5BQ38161453-E423F00E-309B-402A-8323-6CF986E3CCA3Q38207747-1D96EDB2-85EE-44AA-A738-FF4C8F4C64B1Q38610829-96E074C5-EDD5-4848-85BE-3C7D1F069476Q38662765-2FB3CCB2-811F-4B70-8CAC-1B3C73BDB9B7Q38734617-CBDCCA08-C5BC-4452-B178-576537A2C38FQ38837452-0EF66FCA-71EE-407D-B9E2-5C5605E495CBQ38847849-5B5F26E0-F37D-47FF-AF64-4826EDAD1522Q39029023-A2B7C707-1B24-4D1C-9491-A915792085A3Q39062048-5860EABF-065C-4553-B2FB-E999A1F83408Q39280228-96A1F52B-A873-4BA1-B485-30D626D8CB8DQ41129993-BDB57A64-6F80-4783-8F2F-0EF5CB29A8E1Q42506312-F68DFB9B-9382-48A5-93BB-A18F30322D2DQ44635317-69E3A546-5C47-4DD7-889B-83DACC096758Q47779219-C84E6E2D-AC96-4E44-8C2C-80C7D1D958EDQ52684405-89C784FB-E97A-48B3-BC42-4EA597EA62D4Q52699083-A02EED1D-DBBC-49EF-BCFC-76D2F1B9F36FQ53684513-1100F820-B977-4301-B495-76564E38A63F
P2860
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@ast
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@en
type
label
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@ast
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@en
prefLabel
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@ast
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@en
P2093
P2860
P356
P1476
Insulin resistance and metabol ...... r γ-sparing thiazolidinedione.
@en
P2093
Brian N Finck
Jerry R Colca
Kari T Chambers
Mayurranjan S Mitra
Patrick A Vigueira
Rolf F Kletzien
William G McDonald
Zhouji Chen
P2860
P304
23537-23548
P356
10.1074/JBC.M112.363960
P407
P577
2012-05-23T00:00:00Z